Omada Health (NASDAQ:OMDA) Shares Gap Down Following Analyst Downgrade

Key Points

• Omada shares fell sharply after Wells Fargo cut its price target from $22 to $19 while maintaining an equal-weight rating; the stock opened at $16, down from its previous close of $18.95.
• Despite the analyst caution, Omada reported strong third-quarter results: revenue increased 34% to $91 million, membership grew 36% to 1.1 million, and earnings beat estimates. The company also raised its 2026 financial outlook.
• Analyst views remain broadly positive, with a consensus “Moderate Buy” rating and a $26.50 average price target, though executives have also sold shares recently.

Omada Health, Inc. (NASDAQ:OMDA - Get Free Report)'s stock price gapped down prior to trading on Friday after Wells Fargo & Company lowered their price target on the stock from $22.00 to $19.00. The stock had previously closed at $18.95, but opened at $16.00. Wells Fargo & Company currently has an equal weight rating on the stock. Omada Health shares last traded at $15.4060, with a volume of 375,774 shares.

Several other analysts have also recently issued reports on OMDA. JPMorgan Chase & Co. upped their target price on shares of Omada Health from $26.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, August 14th. Weiss Ratings lowered Omada Health from a "sell (d+)" rating to a "sell (d)" rating in a research report on Thursday, October 8th. Barclays reduced their price objective on Omada Health from $27.00 to $24.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 28th. BMO Capital Markets restated an "outperform" rating and set a $24.00 price objective on shares of Omada Health in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded Omada Health from a "hold" rating to a "buy" rating in a research report on Sunday, October 11th. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $26.50.

Insider Buying and Selling

In related news, CEO Sean Duffy sold 21,572 shares of the company's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.62, for a total transaction of $509,530.64. Following the transaction, the chief executive officer directly owned 411,861 shares in the company, valued at approximately $9,728,156.82. This represents a 4.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Steven Cook sold 15,235 shares of the company's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $25.03, for a total value of $381,332.05. Following the transaction, the chief financial officer directly owned 187,209 shares in the company, valued at approximately $4,685,841.27. This represents a 7.53% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 106,070 shares of company stock valued at $2,462,621. Company insiders own 6.38% of the company's stock.

Omada Health News Summary

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Revenue rose 34% year over year to $91 million, and total members grew 36% to a record 1.1 million. Omada also reported $7 million in net income versus a year-ago loss, higher gross margins, and $12 million in adjusted EBITDA. The company raised its full-year 2026 financial outlook. Omada Health Reports Third Quarter 2026 Results
• Positive Sentiment: Quarterly earnings and revenue exceeded analyst estimates, reinforcing the company’s improving operating performance. Q3 Earnings and Revenues Beat Estimates
• Neutral Sentiment: Wells Fargo lowered its price target from $22 to $19 and maintained an equal-weight rating. The new target remains above the quoted share price, but the reduction signals more restrained expectations. Wells Fargo Recommendations
• Negative Sentiment: Zacks Research downgraded Omada from “strong buy” to “hold,” adding to the cautious analyst signals despite the earnings beat. Tickerreport coverage

Institutional Trading of Omada Health

Several institutional investors and hedge funds have recently made changes to their positions in OMDA. China Universal Asset Management Co. Ltd. bought a new stake in Omada Health during the 3rd quarter valued at about $70,000. Sterling Capital Management LLC boosted its position in Omada Health by 1,161.6% in the 3rd quarter. Sterling Capital Management LLC now owns 1,577 shares of the company's stock valued at $33,000 after buying an additional 1,452 shares during the period. Robeco Institutional Asset Management B.V. bought a new position in Omada Health in the 3rd quarter worth about $1,100,000. Counterpoint Mutual Funds LLC bought a new position in Omada Health in the 3rd quarter worth about $595,000. Finally, State of Alaska Department of Revenue purchased a new position in shares of Omada Health during the third quarter worth approximately $59,000.

Omada Health Price Performance

The stock's 50-day moving average price is $20.33 and its 200 day moving average price is $17.74. The firm has a market capitalization of $943.16 million, a PE ratio of 307.98 and a beta of 2.13.

Omada Health (NASDAQ:OMDA - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.08. The company had revenue of $91.31 million for the quarter. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. Equities research analysts forecast that Omada Health, Inc. will post 0.09 earnings per share for the current fiscal year.

Omada Health Company Profile

Omada Health, Inc NASDAQ: OMDA is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.

The company's offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada's technology platform.

Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.